Theriva targets Phase 2/3 VCN-01 trial after early eye-preservation signal

Theriva Biologics is trying to turn a nine-patient pediatric cancer study into a potentially pivotal development program at a time when its financial runway is becoming increasingly important. The company has completed the design of a proposed Phase 2/3 trial combining intravitreal VCN-01 with intravitreal topotecan in children with retinoblastoma whose vitreous seeds are refractory or resistant to existing intravitreal chemotherapy. Theriva Biologics plans to discuss the protocol with the United States Food and Drug Administration during the third quarter of 2026, but the company has not yet disclosed regulatory agreement on the trial or secured the funding required to run it. Cash and cash equivalents stood at $11.3 million on June 30, with management projecting enough resources only into the first quarter of 2027.

The opportunity is nevertheless substantial relative to Theriva Biologics’ current valuation. Earlier Phase 1 testing showed unequivocal improvement in vitreous seed density in four of nine children with treatment-refractory retinoblastoma, while eye removal had been avoided in three patients at the reported follow-up. One of those children had retained the treated eye after four years. Those observations are far too limited to establish efficacy, but they give Theriva Biologics a clinically meaningful rationale for testing whether VCN-01 can help preserve eyes that might otherwise require enucleation.

FDA discussions could determine whether VCN-01 can make an unusually fast jump into late-stage testing

Theriva Biologics said it developed the proposed Phase 2/3 protocol after extensive discussions with key opinion leaders. The planned study would evaluate VCN-01 administered directly into the eye together with topotecan in children whose retinoblastoma remains resistant or refractory to current intravitreal chemotherapy. The company has characterized the population as ultra-rare and one in which no satisfactory current treatment remains once local chemotherapy fails.

A combined Phase 2/3 structure could potentially shorten the path toward registration by allowing preliminary efficacy assessment and confirmatory testing to occur within one broader development program. That possibility remains conditional on FDA feedback. Theriva Biologics has not yet published the proposed enrollment number, primary endpoint, statistical assumptions or regulatory criteria that would allow the study to support a Biologics License Application.

The distinction is important because the program has sometimes been described in forward-looking corporate material as potentially pivotal, but the FDA has not yet endorsed the retinoblastoma trial design publicly. The upcoming meeting therefore represents a value-setting event. Agreement on an endpoint such as durable eye preservation, vitreous seed control or another clinically meaningful outcome could give investors and potential partners a clearer understanding of how much development work remains.

Regulatory incentives could add to the program’s economics. VCN-01 has Orphan Drug designation from both the United States Food and Drug Administration and European Medicines Agency for retinoblastoma, along with Rare Pediatric Disease designation in the United States. Theriva Biologics said that FDA approval of a retinoblastoma Biologics License Application by September 30, 2029 could make the company eligible for a Priority Review Voucher, subject to the applicable program requirements.

That deadline gives Theriva Biologics an additional reason to pursue an efficient development strategy, although it creates an aggressive timetable. The company would need regulatory alignment, financing, trial activation, enrollment, sufficient follow-up and a successful application within roughly three years.

Four responses and three preserved eyes make the Phase 1 result compelling but still highly fragile

The investigator-sponsored Phase 1 trial involved only nine evaluable children with intraocular retinoblastoma that had become refractory to chemotherapy or radiotherapy. Enucleation, the surgical removal of the affected eye, had been the recommended remaining treatment for the participants when they entered the study.

Patients received two intravitreal VCN-01 injections separated by 14 days. One child received 2 × 10^9 viral particles per eye, while eight received 2 × 10^10 viral particles. The study monitoring committee determined that the trial had a positive outcome, with no dose-limiting toxicities and no Grade 3 or higher ocular or systemic toxicities during the assessment period. Most treatment-related adverse events were Grade 1 or Grade 2.

Ocular inflammation and associated vitreous turbidity were observed after treatment in some participants and were managed with local or systemic anti-inflammatory therapy. These effects will remain relevant in a larger study because the treatment is delivered directly into an already diseased eye, making preservation of retinal function and vision central to the benefit-risk calculation.

The efficacy signal was small but clinically interesting. Four children showed unequivocal improvement in vitreous seed density, and enucleation had been avoided in three at the reported follow-up. The longest-followed child had retained the eye after four years.

Those numbers should not be converted into a conventional response rate and projected onto a larger trial. Every patient represents more than 11% of the nine-person dataset, and the uncontrolled Phase 1 study was principally designed around safety and tolerability rather than proving VCN-01 efficacy. The proposed Phase 2/3 program would also add topotecan, meaning its regimen will differ from the original VCN-01-only clinical experience.

That difference could be an advantage if preclinical synergy between VCN-01 and topotecan translates into stronger tumor control. It also makes the next study the first real test of the combination that Theriva Biologics ultimately hopes could become a treatment strategy.

VCN-01’s broader cancer platform raises the upside while Theriva’s financing needs limit flexibility

VCN-01 is an engineered oncolytic adenovirus designed to selectively replicate within tumor cells, kill those cells and degrade the tumor stroma that can act as both a physical and immunosuppressive barrier to treatment. Theriva Biologics is evaluating the platform through several routes of administration, including intravenous and intravitreal delivery.

Retinoblastoma is only one component of the VCN-01 strategy. Theriva Biologics has begun dosing patients in VIRAGE2, a six-patient Phase 2a study evaluating at least three intravenous doses of VCN-01 alongside gemcitabine and nab-paclitaxel in newly diagnosed metastatic pancreatic ductal adenocarcinoma. Enrollment is expected to finish during the second half of 2026, with initial pharmacodynamic and safety data targeted for the third quarter of 2027.

The pancreatic program means Theriva Biologics is simultaneously trying to optimize systemic VCN-01 dosing while preparing for a possible pediatric Phase 2/3 trial. The company has also generated clinical data in head and neck squamous cell carcinoma, where earlier VCN-01 research explored whether degrading tumor stroma and modifying the immune environment could restore sensitivity to checkpoint inhibition.

A platform with several indications offers multiple opportunities for value creation, but the strategy becomes more difficult with only $11.3 million of cash. Research and development expenses were relatively modest at $1.3 million during the second quarter, partly reflecting lower spending on older programs, while VCN-01 manufacturing and pancreatic cancer development costs increased. The company recorded a second-quarter net loss of $3.2 million and a six-month net loss of $5.3 million.

Theriva Biologics explicitly states that commencement of planned studies remains subject to sufficient financing and identifies capital raising, development funding and partnerships as important variables affecting future clinical work. Its separate SYN-004 study has already paused enrollment pending grant, partnership or other funding, illustrating that financial constraints are not theoretical.

The most logical financing route could therefore involve a strategic partnership around VCN-01 or new equity capital following favorable FDA feedback. A defined Phase 2/3 regulatory pathway would potentially make the retinoblastoma program easier to finance because investors could estimate trial size, timing and regulatory milestones more accurately. That is an inference from Theriva Biologics’ funding position rather than a financing plan announced by the company.

TOVX valuation shows investors see substantial execution risk despite cash exceeding market value

Theriva Biologics shares were trading around $0.23 late on August 11, virtually unchanged from the previous close, with an intraday range of approximately $0.223 to $0.235. The company’s market capitalization stood near $9.45 million.

That market capitalization is below the $11.3 million of cash and cash equivalents reported at June 30. The comparison is striking but does not mean Theriva Biologics is automatically undervalued. The company also reported $22.7 million in total liabilities, continues to consume cash and would require substantially more capital if the proposed retinoblastoma Phase 2/3 program and broader VCN-01 strategy advance.

The valuation instead appears to reflect unusually cautious sentiment toward future execution. Investors must weigh a potentially high-value rare pediatric cancer opportunity against the absence of FDA agreement on the proposed study, very limited Phase 1 efficacy evidence, an ultra-rare recruitment population and a cash runway that ends well before a Phase 2/3 trial could plausibly produce registrational data.

A favorable FDA meeting could improve that equation. Theriva Biologics would still need money, but regulatory clarity could transform the retinoblastoma program from a concept based on nine children into a defined late-stage development opportunity. Conversely, requirements for a larger or more complex program would make the company’s financial constraints more pressing.

VCN-01 has produced enough early evidence to justify that discussion. The three children who avoided enucleation offer a powerful clinical reason to continue investigating the treatment, but they do not provide the statistical evidence needed for approval. Theriva Biologics’ next challenge is therefore as financial as it is clinical: securing a credible regulatory pathway and enough capital to test whether those isolated eye-preservation outcomes can be reproduced across a larger pediatric population.

Key takeaways on what the VCN-01 Phase 2/3 plan means for Theriva Biologics

• Theriva Biologics has completed the design of a proposed Phase 2/3 retinoblastoma trial combining intravitreal VCN-01 with intravitreal topotecan and plans FDA discussions during the third quarter of 2026.
• The FDA has not yet publicly agreed to the proposed retinoblastoma design, making the coming regulatory discussion an important development milestone.
• Earlier Phase 1 testing involved only nine children, with four showing unequivocal improvement in vitreous seed density and three avoiding enucleation at the reported follow-up.
• No dose-limiting toxicities or Grade 3 or higher ocular or systemic toxicities were reported during the Phase 1 evaluation period, although ocular inflammation occurred in some participants.
• VCN-01 has FDA and European Medicines Agency Orphan Drug designations for retinoblastoma and an FDA Rare Pediatric Disease designation.
• Theriva Biologics says approval by September 30, 2029 could potentially qualify the program for a Priority Review Voucher under the applicable rare pediatric disease framework.
• The company had only $11.3 million in cash at June 30 and expects its current runway to extend into the first quarter of 2027.
• Theriva Biologics is simultaneously funding VCN-01 development in metastatic pancreatic cancer, increasing competition for its limited capital resources.
• TOVX traded near $0.23 on August 11 with a market capitalization of approximately $9.45 million, below the company’s reported cash balance but not its total liabilities.
• Investor sentiment remains highly cautious, and favorable FDA feedback plus additional financing are likely to be necessary before the retinoblastoma program can become a credible late-stage value driver.